The specter of generic rivalry has repeatedly loomed above copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the prospects of related drug holdings. While early periods saw significant profits, the exclusivity expiration has created the way for discounted substitutes, likely reducing revenue and presenting a genuine hazard for s